Chen Richard Z, Huang Ruey-Ruey C, Shen Chun-Pyn, MacNeil Douglas J, Fong Tung M
Department of Metabolic Disorders, PO Box 2000, RY80M-213, Rahway, NJ 07065, USA.
Brain Res. 2004 Mar 5;999(2):227-30. doi: 10.1016/j.brainres.2003.12.004.
Oral administration of the opioid antagonist nalmefene alone (up to 20 mg/kg) failed to show a significant effect on acute food intake in mice. However, combined oral dosing of nalmefene and subthreshold doses of AM251, a cannabinoid CB1 receptor inverse agonist, led to a significant reduction in food intake in both lean and diet-induced obese (DIO) mice. Furthermore, the anorectic effect of a high dose of AM251 was further enhanced when co-administered with nalmefene. The results support a synergistic interaction between opioid and cannabinoid systems in regulating feeding behavior.
单独口服阿片类拮抗剂纳美芬（剂量高达20毫克/千克）对小鼠的急性食物摄入量未显示出显著影响。然而，纳美芬与低于阈剂量的大麻素CB1受体反向激动剂AM251联合口服给药，导致瘦小鼠和饮食诱导肥胖（DIO）小鼠的食物摄入量均显著减少。此外，高剂量AM251与纳美芬共同给药时，其厌食作用进一步增强。这些结果支持阿片类和大麻素系统在调节进食行为方面存在协同相互作用。
